Shares in Novo Nordisk plummeted Thursday following Hims & Hers Health Inc.'s introduction of a lower-cost version of the weight-loss drug Wegovy. The Danish pharmaceutical giant has declared the move illegal. Bloomberg Intelligence's Michael Shah noted the market's reaction. This development immediately impacts the competitive landscape for weight-loss medications.

This is a direct challenge to Novo Nordisk's market dominance in the rapidly growing weight-loss drug sector. Wegovy, along with Ozempic, has been incredibly popular. Hims & Hers' move could pressure Novo Nordisk's sales and pricing strategies. Legal battles are likely to ensue over intellectual property rights.

The launch highlights the growing demand for accessible weight-loss treatments. While details are still emerging, Hims & Hers is attempting to capitalize on the popularity of GLP-1 receptor agonists. Investors will be watching the legal proceedings and the long-term market impact.

Next, the market will assess the efficacy and safety of Hims & Hers' offering. Any regulatory scrutiny of their product will be key. Moreover, the response from other pharmaceutical companies to this competitive threat will be something to watch. The situation is evolving rapidly.